Intrinsic Value

The intrinsic value of Equasens SA (PHF) under the Base Case is 36.57 EUR per share. Compared with the current market price of 52.77 EUR, the stock appears Overvalued by 31% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

PHF Intrinsic Value
€36.57
Overvaluation 31%
Intrinsic Value
Price €52.77

PHF is more expensive than usual. This is its most expensive valuation in the past 5 years.

Monitor PHF
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €29.26
Get notified when the price drops into your buy zone
Current Price €52.77
Intrinsic Value €36.57
Margin of Safety 20% €29.26
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to PHF

Fundamental Analysis

What Equasens Does

Health Care

Equasens SA is a French software and technology company focused on the healthcare sector. It builds and sells digital tools that help pharmacies, doctors, nurses, hospitals, and care facilities manage prescriptions, patient records, billing, and day-to-day administration. Its products are designed to sit inside the workflow of healthcare professionals, so the company is less of a general IT vendor and more of a specialist provider for regulated medical and pharmacy businesses.

Headquarters
France FR
Employees
1 400
IPO date
Oct 20, 2000
Read the full company overview
View Company Overview

Equasens has no economic moat

No Moat Narrow Wide

Equasens SA lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.

Read the full moat analysis
Financials
Efficiency

Earnings Waterfall
Equasens SA

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one PHF stock?

The intrinsic value for Equasens SA (PHF) under the Base Case is 36.57 EUR.

Is PHF stock undervalued or overvalued?

Compared with the current market price of 52.77 EUR, the stock appears Overvalued by 31% .

Back to Top